<DOC>
	<DOCNO>NCT01959061</DOCNO>
	<brief_summary>To evaluate efficacy safety Raltitrexed advance colorectal cancer</brief_summary>
	<brief_title>Efficacy Safety Raltitrexed-based Transarterial Chemoembolisation ( TACE ) Colorectal Cancer Liver Metastases</brief_title>
	<detailed_description>evaluate efficacy safety Raltitrexed oxaliplatin lipiodol transcatheter arthrial chemoembolization refractory colorectal carcinoma liver metastasis .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Raltitrexed</mesh_term>
	<mesh_term>Ethiodized Oil</mesh_term>
	<criteria>1 . Histologically confirm colorectal adenocarcinoma 2 . Disease limit liver Unresectable disease surgery local therapy 3 . Age &gt; 18 year 4 . ECOG performance status 02 , Child pugh A B 5 . Expected survival â‰¥ 3 month 6 . Adequate hematological , hepatic , renal function 1 . Pregnant lactate woman 2 . Patients severe organ dysfunction failure 3 . With severe cardiovascular disease , mental 4 . Extraliver metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Advanced colorectal cancer liver metastatic</keyword>
</DOC>